Eton Pharmaceuticals ( (ETON) ) has released its Q2 earnings. Here is a breakdown of the information Eton Pharmaceuticals presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eton Pharmaceuticals is an innovative pharmaceutical company that focuses on developing and commercializing treatments for rare diseases. The company has a diverse portfolio of commercial products and is actively advancing several late-stage product candidates.
In its second quarter of 2025, Eton Pharmaceuticals reported significant financial growth, with product sales reaching $18.9 million, marking a 108% increase compared to the same period in the previous year. The company also launched KHINDIVI, the first FDA-approved oral solution of hydrocortisone, and surpassed its target of 100 active INCRELEX patients ahead of schedule.
Key financial highlights for the quarter include a gross profit of $11.9 million, an adjusted EBITDA of $3.1 million, and a non-GAAP net income of $1.5 million. The company’s revenue growth was primarily driven by the continued success of ALKINDI SPRINKLE and the relaunches of INCRELEX and GALZIN. Eton also reported a strong cash position with $25.4 million in cash and cash equivalents.
Looking ahead, Eton Pharmaceuticals anticipates reaching an annual revenue run rate of $80 million in the third quarter of 2025, one quarter ahead of its previous guidance. The company is also preparing for the potential approval and launch of ET-600 in early 2026, reflecting its ongoing commitment to expanding its product offerings and market presence.